CAD 0.03
(0.0%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 96.34 Thousand CAD | -43.73% |
2022 | 171.21 Thousand CAD | -59.71% |
2021 | 424.92 Thousand CAD | -35.89% |
2020 | 662.76 Thousand CAD | 24.78% |
2019 | 531.16 Thousand CAD | 227.09% |
2018 | 162.39 Thousand CAD | 0.0% |
2017 | - CAD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 827.00 CAD | -88.95% |
2024 Q2 | 887.00 CAD | 7.26% |
2023 Q2 | 37.28 Thousand CAD | 175.35% |
2023 Q4 | 7485.00 CAD | -80.32% |
2023 FY | 96.34 Thousand CAD | -43.73% |
2023 Q3 | 38.03 Thousand CAD | 2.01% |
2023 Q1 | 13.54 Thousand CAD | -63.09% |
2022 Q2 | 34.29 Thousand CAD | -45.33% |
2022 Q4 | 36.68 Thousand CAD | -2.2% |
2022 Q3 | 37.51 Thousand CAD | 9.38% |
2022 Q1 | 62.72 Thousand CAD | -8.4% |
2022 FY | 171.21 Thousand CAD | -59.71% |
2021 Q4 | 68.47 Thousand CAD | -31.18% |
2021 FY | 424.92 Thousand CAD | -35.89% |
2021 Q2 | 127.75 Thousand CAD | -1.13% |
2021 Q1 | 129.2 Thousand CAD | -39.67% |
2021 Q3 | 99.49 Thousand CAD | -22.12% |
2020 Q3 | 185.82 Thousand CAD | 11.1% |
2020 Q2 | 167.27 Thousand CAD | 75.16% |
2020 Q1 | 95.49 Thousand CAD | -31.33% |
2020 FY | 662.76 Thousand CAD | 24.78% |
2020 Q4 | 214.17 Thousand CAD | 15.25% |
2019 Q3 | 191.8 Thousand CAD | 80.83% |
2019 Q4 | 139.05 Thousand CAD | -27.5% |
2019 FY | 531.16 Thousand CAD | 227.09% |
2019 Q2 | 106.06 Thousand CAD | 12.56% |
2019 Q1 | 94.23 Thousand CAD | 29.84% |
2018 Q2 | 38.81 Thousand CAD | 64596.67% |
2018 FY | 162.39 Thousand CAD | 0.0% |
2018 Q4 | 72.58 Thousand CAD | 42.51% |
2018 Q3 | 50.93 Thousand CAD | 31.21% |
2018 Q1 | 60.00 CAD | 0.0% |
2017 FY | - CAD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
AI/ML Innovations Inc. | 294.86 Thousand CAD | 67.327% |
Diagnamed Holdings Corp. | - CAD | -Infinity% |
Pangenomic Health Inc. | - CAD | -Infinity% |
Treatment.Com International Inc. | - CAD | -Infinity% |
Unidoc Health Corp. | - CAD | -Infinity% |